IR PRESENTATION

April 2026

PRECISION TO THE POINT

SAFE HARBOR STATEMENT

Forward-looking statements involve risks.

This company presentation contains various statements concerning the future performance of STRATEC. These statements are based on both assumptions and estimates. Although we are convinced that these forward-looking statements are realistic, we can provide no guarantee of this. This is because our assumptions involve risks and uncertainties which could result in a substantial divergence between actual results and those expected.

It is not planned to update these forward-looking statements.

STRATEC AT A GLANCE

- Leading OEM player for automation solutions for the diagnostics industry and translational research
- Three decades of experience in highly regulated healthcare markets and growing technology pool
- Around 1.400 employees worldwide
  - Around 50% allocable to R&D
- Production sites in Germany (HQ), Switzerland, Hungary, Austria and in the United States
- High number of systems installed globally
  - More than 50,000 systems
- Sales of € 257.6 million in 2024
  - CAGR sales since IPO in 1998: ~13%
- Sales split 2024:
  - Systems 32%
  - Service parts and consumables 43%
  - Development and services 25%

UNIQUE POSITION WITHIN THE VALUE CHAIN

STRATEC provides instrumentation, consumables, software and automation solutions

- OEM development and manufacturing
- Several thousand automated analyzer systems manufactured annually
- Wide range of intellectual property rights / broad technology pool

Long market lifecycles lead to longstanding partnerships

- Product lifecycles for a system typically in an area of 12 to 15 years
- Expanding installed base of systems
- Product enhancement and extension drives value / Life cycle management

Long-term contractual setup

- Milestone payments during development stage (linked to agreed development budget and development targets)
- Operating sales during series production stage - minimum volume commitment by partner, firm transfer price)
- Recurring sales from service parts & consumables

→ **strong commitment by both partners**

Shared responsibilities



Indicative revenue characteristics of an analyzer OEM project



ACTIVE IN FAST GROWING SEGMENTS

IVD MARKET SEGMENTS / IVD MARKET: ~90 BILLION USD

Focus on market segments with above average complexity and growth

Molecular Diagnostics
- Random access analyser systems (mid-to-high throughput)
- Smart consumables (multiplexing)
- POC devices (multiplexing) with smart consumables

Immunoassay
- Random access analyzer systems (mid-to-high throughput)
- Classic plastic consumables
- Smart consumables

Hematology & other routine testing
- Decentralized testing solutions
- Veterinary diagnostics
- Plastics

Further specialities / focus areas
- Immunohematology
- Complex Sample Processing
- Tissue Diagnostics
- Translational Research

IVD market by technologies



IVD market by product group



Source: MarketsandMarkets Research; own estimates

BENEFITTING FROM OUTSOURCING TREND

OUTSOURCED VS IN HOUSE INSTRUMENTATION MARKET

The majority of instrumentation equipment in the IVD market is still developed in-house by diagnostics companies.

Share of outsourced developments has already increased significantly over the last couple of years.

Trend of outsourcing towards specialized players set to continue, due to:

- Engineering of automation solutions often not core competence of diagnostics companies
- Shorter development timeframes due to already existent technology pools
- Guaranteed project budget and firm transfer prices
- Keeping up with regulatory developments easier for specialized players
- Structured processes in order to address end customer needs, such as ease of use, user experience, workflow efficiencies, remote access, serviceability and preventive maintenance

Proportion of outsourced instrumentation developments over time

Past

Ongoing paradigm shift even within the „blue chips“ towards outsourcing

STRONG RECURRING REVENUE BASE

Service parts and consumables (43% of sales)

- Maintenance parts
- Spare parts
- Classic plastic consumables (eg. Pipetting tips, reaction vessels)
- Smart consumables (highly complex cartridges; microfluidics, molding, mastering and coating technologies)

Fueled by growing installed base and increasing complexity

- Continuously growing number of active systems in the lab
- Strong upward trend in the average complexity of systems

Smart consumables



SIMOA™ 24-ASSAY DISC
Quanterix

VITEK® MS
Disposable target slide
bioMérieux

Service and spare parts

Perestaltic Pump
STRATEC

Classic consumables

Stackable Cuvette
STRATEC

Installed base[1]



[1] Estimated with the assumption of an average six year replacement cycle in the lab

Sales split 2024

stratec

STRONG LONG-TERM CUSTOMER RELATIONSHIPS

A SELECTION OF STRATEC CUSTOMERS

	GLOBAL TOP 20 IVD COMPANIES	Sales 2024 (USD billion)
1.	Roche	16.9
2.	Danaher	9.9
3.	Abbott	9.3
4.	Siemens	4.8
5.	Thermo Fisher	4.5
6.	Becton Dickinson	3.7
7.	bioMerieux	3.7
8.	Sysmex	3.1
9.	Exact Sciences	2.8
10.	QuidelOrtho	2.8
11.	Illumina	2.4
12.	CH Werfen (Inova, IL, Biokit)	2.3
13.	Shenzhen Mindray	1.9
14.	Hologic	1.8
15.	Natera	1.7
16.	Agilent Tech	1.7
17.	Bio-Rad	1.5
18.	Revvity (formerly PerkinElmer)	1.5
19.	DiaSorin	1.3
20.	Diagnostica Stago	1.0

… And other technology pioneers

Cytovale

Quanterix

STRATEC customer   Not a STRATEC customer

Source: IVD News / non-public companies estimated / non-reported sector sales estimated

MARKET – FOCUS AREAS

HIGH-SENSITIVITY IMMUNOASSAYS

EXPAND DOMINANT MARKET POSITION WITH INNOVATORS AND ESTABLISHED PLAYERS

Focus Areas:
- High-Multiplexing up to full proteome
- Single Molecule Detection Technologies
- High-Throughput rare-biomarker screening (Neuro-Degenerative Diseases)

How STRATEC can capitalize:
- Dominant market position and established trustful partnerships with leading players
- Comprehensive offering through combined pool of instrument and consumable technologies

Market trends:
- Transfer of single molecule technologies into the clinical labs
- Breakthrough discoveries in neurodegenerative diseases triggers demand for diagnostic assays and therapy monitoring solutions

Proteomics Research Market: $2.0bn



Source: Customer information

MARKET – FOCUS AREAS

ADVANCED IMAGING

DYNAMIC MARKET WITH EXPECTED PUSH BY AI

Focus Areas:

- Automation for digital imaging allowing for the combination of traditional H&E stains with custom fluorescence labels
- Sample prep workflows allowing for flexibility to add different sample types and quality

How STRATEC can capitalize:

- Use of the common modules and proven reliability of their interplay allowing for highly cost effective systems
- Flexible hardware & software architecture to ensure interoperability and long-term system sustainability
- Strong software team including data-scientists to exploit AI enabled workflows at a rapid pace

Market trends:

- High-Content, High Resolution imaging providing powerful datasets for both clinical research and prognostic healthcare

Total addressable tools market – Advanced Imaging [1]



[1] Excluding in-vitro diagnostics
Source: DeciBio, own estimates

stratec

CELL & GENE THERAPY

FAST-GROWING MARKET WITH UNMET NEED FOR AUTOMATION

Focus Areas:

- Cell Isolation (sorting and isolation of cell types of interest)
- Transfection (genetic engineering of cells to create the therapy)

How STRATEC can capitalize:

- Significant need for automation across the entire workflow to lower cost per treatment and improve access
- Need for high-throughput platforms for gene transfer, cell sorting, and cell expansion
- Decentralization of the workflow: Providing safety and efficacy

Market trends:

- Increasing prevalence of complex and chronic diseases
- Transformation of traditional blood-products / blood-banking applications to cell & gene therapy
- New research expands market into new large indications (e.g. autoimmune disorders)

Total addressable tools market – Cell Therapy



Source: DeciBio, own estimates

stratec

HIGHLIGHTS AND ACHIEVEMENTS

Positive sales **growth** despite supply chain interruptions and thanks to **high development activity** as well as further **stabilization** in **molecular system** demand

Margin development **held back** by **product mix effects** and **FX** headwinds

Progress in **development partnerships** and significant **upturn** in **demand** in the area of **system development**

Lower end of 2025 **margin guidance confirmed** despite **lowered sales outlook** as **efficiency** measures unfold momentum strateco

FINANCIALS 9M/2025 AT A GLANCE[1]

€ 000s	9M/2025	9M/2024[2]	Change	Q3/2025	Q3/2024[2]	Change
Sales	175,588	172,958	+1.5% (cc: +2.5%)	56,998	60,267	-5.4% (cc: -3.4%)
Adjusted EBITDA	24,235	26,623	-9.0%	8,165	9,197	-11.2%
Adjusted EBITDA margin (%)	13.8	15.4	-160 bps	14.3	15.3	-100 bps
Adjusted EBIT	12,824	15,149	-15.3%	4,337	5,269	-17.7%
Adjusted EBIT margin (%)	7.3	8.8	-150 bps	7.6	8.7	-110 bps
Adjusted consolidated net income	7,104	8,434	-15.8%	2,126	2,831	-24.9%
Adjusted basic earnings per share (in €)	0.58	0.69	-15.9%	0.17	0.23	-26.1%
Basic earnings per share IFRS (in €)	0.34	0.39	-12.8%	0.13	0.06	+116.7%

bps = basis points
cc = at constant currency

[1] To facilitate comparison, figures for 2025 have been adjusted to exclude amortization resulting from purchase price allocations in the context of acquisitions and other non-recurring items (including one-off advisory expenses, fees, and restructuring expenses). The figures for 2024 have additionally been adjusted to exclude one-off personnel expenses of € 1.7 million in connection with the departure of a member of the Board of Management.
[2] Restated pursuant to IAS 8.

stratec

ADJUSTMENTS 9M/2025

EBIT

€ 000s	9M/2025	9M/2024[2]
Adjusted EBIT	**12,824**	**15,149**
Adjustments:		
PPA amortization	-2,309	-2,772
Other[1]	-1,677	-2,052
EBIT	**8,838**	**10,325**

[1] Including one-off advisory expenses, fees, and restructuring expenses
[2] Restated pursuant to IAS 8

Consolidated net income

€ 000s	9M/2025	9M/2024[2]
Adjusted consolidated net income	**7,104**	**8,434**
Adjusted earnings per share in € (basic)	**0.58**	**0.69**
Adjustments:		
PPA amortization	-2,309	-2,772
Other[1]	-1,677	-2,052
Taxes on income	985	1,156
Consolidated net income	**4,103**	**4,766**
Earnings per share in € (basic)	**0.34**	**0.39**

[1] Including one-off advisory expenses, fees, and restructuring expenses
[2] Restated pursuant to IAS 8

FINANCIAL REVIEW

SALES 9M/2025



cc = at constant currency

9M/2024 restated pursuant to IAS 8

As of September 30

9M/2025 sales +2.5% yoy in constant currency to € 175.6 million

- Double digit growth with Development and service sales due to high development activity and high number of active customer projects

---

- Subdued ramp-up curves for newly launched products
- Supply chain driven delivery shortfalls
- Volatile customer order behavior
- Low but stabilizing demand for MDx systems following pandemic related disruptions

stratec

ADJUSTED EBIT AND EBIT MARGIN 9M/2025



9M/2024 restated pursuant to IAS 8

As of September 30

9M 2025 adj. EBIT -15.3% to 12.8 million €

Margin -150 bps YoY to 7.3%

- Efficiency measures and structural changes taking effect

- Gross margin down due to subdued product mix in the systems business and lower share of high margin Service parts & consumables sales in Q3/2025
- Negative currency effects

€ 000s	9M/2025	9M/2024
Research and development expenses	-7,012	-8,123
Sales-related expenses	-8,973	-9,992
General administrative expenses	-18,992	-18,597
Income / Expenses from impairment of financial assets and contract assets	-614	-11
Other operating income and expenses	-828	-238

CASH FLOW AND NET DEBT

€ 000s	9M/2025	9M/2024	Change
Cash flow – operating activities	-1,435	25,430	nm
Cash flow – investment activities	-13,375	-12,432	nm
Cash flow – financing activities	-8,971	-13,482	nm
Free cash flow	-14,810	+12,998	nm

€ 000s	9M/2025	FY/2024	Change
Cash	22,396	47,164	-52.5%
Equity ratio (%)	55.7	54.5	+120 bps
Net debt	109,846	87,096	+26.1%

- **Operating cash flow dynamics 9M/2025** burdened by high cash tax payments, decrease in trade payables and not yet materialized inventory reduction; Positive operating cash flow of € 4.4 million in Q3/2025
- Strong focus to **reduce still elevated inventory** levels going forward

€ 000s	9M/2025	FY/2024
Inventories	126,389	121,818
Trade receivables	41,947	41,578
Trade payables	14,418	18,447

- **Investment ratio[1] at 7.3%** of sales below projected corridor for FY 2025 of 8.0% to 10.0%
- **Net debt / LTM EBITDA** at **2.4x** (up from 1.9x at the end of FY 2024)
- Negotiations on refinancing of bridge loan by a new **€ 125 million syndicated loan** concluded and agreement signed in Q3/2025

[1] Total investments in intangible and tangible assets in % of sales
LTM = Last twelve months

SALES BY OPERATING DIVISIONS H1/2025





cc = at constant currency

H1/2024 restated pursuant to IAS 8

As of June 30

SALES AND EBIT MARGIN



cc = at constant currency

As of December 31

Sales 2025 -2.6% to € 250.9 million (constant currency: -1.1%)

- Return to growth in system sales
- Further stabilization in demand for system lines that had seen disruptions in the wake of the COVID-19 pandemic

- High earnings contributions from development and services in the prior year did not recur, as expected
- Trade policy tensions and geopolitical crises affect customer ordering behavior and supply chain stability

OUTLOOK

FINANCIAL GUIDANCE FOR FISCAL YEAR 2026

Consolidated sales for the 2026 financial year expected to grow in a medium to high single-digit percentage on a constant currency basis

- Robust demand for systems in the fields of immunoassays and immunohematology and a slight recovery in the field of molecular diagnostics

Adjusted EBIT margin on previous years level (FY 2025: 10,0%)

- Benefits of scale are expected to be partly to fully offset by rising input costs attributable to factors including the impact of geopolitical conflicts.

Based on intra-year order forecasts, sales growth will predominantly materialize in the second half of 2026, while the first quarter is expected to see a sharp reduction in sales, accompanied by an associated dip in profitability, not least due to the high volume of development sales realized in the previous year.

New mid-term targets to be announced with the publication of the 2025 Annual Report on 28 April 2026

FOCUS IN 2026 AND BEYOND

Maintaining cost discipline throughout the company given earnings improvement measures implemented

Continue to **grow footprint** in selected **market focus areas** (High-Sensitivity Immunoassays, Advanced Imaging, Cell & Gene Therapy)

Manage and process **well filled M&A pipeline** according to external growth and diversification strategy

Execute deal pipeline regarding new development and manufacturing agreements

Execute on **localisation strategy** despite growing **efforts** in **development** and **regulatory**

Improve **cash flow dynamics** with **strong focus** on **inventory efficiency**

CORPORATE SOCIAL RESPONSIBILITY

ECOLOGICAL RESPONSIBILITY

FOR A BETTER TOMORROW

- Global Environmental Policy outlines the guiding principles and minimum standards of our environmental strategy.
- Developed transition plan that outlines the strategic measures and steps required to achieve our climate goals
- Signatory to the UN Global Compact of the United Nations
- STRATEC reduced its total Scope 1 and 2 emissions by 36% since 2019

SOCIAL RESPONSIBILITY

TOWARDS PEOPLE AND SOCIETY

- Strong policies and measures to promote an open, tolerant and discrimination-free corporate culture
- Extensive occupational health/safety policies and programs
- Formulated goals for diversity and health/safety KPI's with corresponding monitoring

CORPORATE GOVERNANCE

AS A BASIS FOR TRUST AND TRANSPARENCY

- Compliance management system in place to assure compliance with all national/international legislation
- ESG Board in place to identify and manage risks/opportunities related to sustainability.

SCIENCE BASED TARGETS
DRIVING AMBITIOUS CORPORATE CLIMATE ACTION

THE NET ZERO STANDARD
APPROVED NET-ZERO TARGETS

Climate targets[1] validated by the Science Based Targets initiative (SBTi) and thus consistency with the target set by the Paris Agreement of limiting global warming to 1.5°C.

[1] Short-term targets: Reduction of absolute greenhouse gas emissions in Scope 1, 2 and 3 by 50,4% by 2032 compared with the 2023 base year | Long-term targets: Reduction of absolute greenhouse gas emissions in Scope 1, 2 and 3 by 90% by 2045 compared with the 2023 base year | Net zero targets: STRATEC is committed to achieving net zero greenhouse gas emissions throughout its value chain by 2045

APPENDIX

ADJUSTMENTS FY2024

EBIT

€ 000s	FY 2024	FY 2023
Adjusted EBIT	**33,459**	**30,388**
Adjustments:		
PPA amortization	-3,679	-3,188
Other[1]	-2,238	-1,496
EBIT	**27,542**	**25,704**

[1] Advisory expenses and restructuring costs in connection with M&A activities as well as one-off personnel expenses

Consolidated net income

€ 000s	FY 2024	FY 2023
Adjusted consolidated net income	**20,496**	**19,009**
Adjusted earnings per share in € (basic)	**1.69**	**1.56**
Adjustments:		
PPA amortization	-3,679	-3,188
Other[1]	-2,238	-1,496
Taxes	1,442	1,045
Consolidated net income	**16,021**	**15,370**
Earnings per share in € (basic)	**1.32**	**1.26**

[1] Advisory expenses and restructuring costs in connection with M&A activities as well as one-off personnel expenses

KEY FIGURES AT A GLANCE[1]

IFRS (€ million)	2020	2021	2022	2023[2]	2024
Sales	250.1	287.3	274.6	270.4	257.6
Adjusted EBIT	41.7	54.3	45.1	30.4	33.5
Adjusted EBIT margin (%)	16.7	18.9	16.4	11.2	13.0
Adjusted consolidated net income	35.2	45.1	34.7	19.0	20.5
Adjusted earnings per share (€)	2.92	3.73	2.86	1.56	1.69
Dividend per share (€)	0.90	0.95	0.97	0.55	0.60
No. of employees	1,319	1,398	1,481	1,522	1,450
Total assets	331.9	368.5	397.5	450.7	455.0
Equity ratio (%)	52.0	55.8	56.6	52.6	54.5
Free cash flow	10.0	43.3	-8.7	-24.7	33.7

[1] For comparison purposes, adjusted figures have been adjusted to exclude amortization from purchase price allocations in the context of acquisitions, as well as for other one-off items (consulting and reorganization expenses in connection with M&A activities and one-off personnel expenses).
[2] Restated in accordance with IAS 8. 2

SHAREHOLDER STRUCTURE

(AS OF: MAY 2025)



Institutional investors > 3%:
- Brown Capital Management
- Aalap Mahadevia / Briarwood Capital Partners LP
- Morgan Stanley
- JPMorgan Chase & Co.
- Juno Investment Partners

SHARE

IPO	Aug. 1998
Number of shares	12,157,841
Share price (April 13, 2026)	€ 17.32
Market capitalization	€ 211 million

CONTACT

STRATEC SE
Gewerbestr. 37
75217 Birkenfeld
Germany

Phone +49 7082 7916-0
Fax +49 7082 7916-999
www.stratec.com



THANK YOU FOR YOUR ATTENTION

CONTACT

Jan Keppeler, CFA
Head of Investor Relations, Sustainability & Corporate Communications

Phone +49 7082 7916-6515
j.keppeler@stratec.com